Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  DAIICHI SANKYO COMPANY, LIMITED    4568   JP3475350009

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Daiichi Sankyo Co : Daiichi Sankyo to Develop Narcotic Analgesic Hydromorphone Hydrochloride in Japan

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/24/2012 | 07:59am CEST

For Immediate Release
Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, President and Representative Director
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges) Please address inquiries to Toshiaki Sai, General Manager, Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com/

Daiichi Sankyo to Develop Narcotic Analgesic Hydromorphone Hydrochloride in Japan Tokyo, Japan (March 23, 2012) - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it will develop hydromorphone hydrochloride, a narcotic analgesic that has yet to be approved in Japan.

Hydromorphone hydrochloride is an opiate, narcotic analgesic that has been available outside of Japan for over 80 years. Although it is the standard for pain management for cancer pain treatment according to WHO guidelines, hydromorphone hydrochloride has yet to be approved in Japan.
Mundipharma K.K. had been requested by the Study Group on Unapproved and Off-label Drugs of High Medical Need* to develop hydromorphone hydrochloride in Japan, but after subsequent discussions it was decided that Daiichi Sankyo would develop the drug instead. The development of hydromorphone hydrochloride will contribute to the improvement of pain management options in Japan, and Daiichi Sankyo, through its commitment to corporate social responsibility, will continue to work to make unapproved and off-label drugs available in Japan in order to further contribute to medical treatment options for patients.
*A study group set up by Japan's Ministry of Health, Labour and Welfare to promote development by pharmaceutical companies of unapproved and off-label drugs in Japan that have been approved in the United States and Europe.
###

distributed by

This press release was issued by Daiichi Sankyo Co. Ltd. and was initially posted at http://www.daiichisankyo.com/news/20120321_376_E2.pdf . It was distributed, unedited and unaltered, by noodls on 2012-03-24 07:53:56 AM. The issuer is solely responsible for the accuracy of the information contained therein.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on DAIICHI SANKYO COMPANY, LI
10/16 DAIICHI SANKYO : Announces Support from the Japan Agency for Medical Research an..
10/12 Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo Conduct 'JOINUS,' a Ne..
10/10 DAIICHI SANKYO : to Install Call Center Support System in Japan Utilizing Artifi..
10/05 DAIICHI SANKYO : Research Data from Daiichi Sankyo Update Understanding of Mesen..
10/05 EXELIXIS : Provides Update on Collaborator Daiichi Sankyo's Phase 3 Clinical Pro..
10/05 DAIICHI SANKYO : Subsidiaries of Gucci and Daiichi go in for voluntary liquidati..
10/05 DAIICHI SANKYO : Gucci, daiichi to disband india units
10/03 DAIICHI SANKYO : Underwrites All Shares Issued by Kitasato Daiichi Sankyo Vaccin..
09/28 DAIICHI SANKYO : Announces TaNeDS Global 2018 Collaborative Drug Discovery Progr..
09/27 DAIICHI SANKYO COMPANY, LIMITED : ex-dividend day for interim dividend
More news
News from SeekingAlpha
09/26 YOUR DAILY PHARMA SCOOP : Alnylam's Big Win, Aradigm NDA And Rating, EXEL And AZ..
09/25 Exelixis up 2% premarket on positive late-stage data on hypertension candidat..
09/14 Daiichi teams up with MD Anderson to accelerate new leukemia therapies
08/31 Daiichi backs out of hydrocodone development partnership with Charleston Labs..
08/31 Daiichi Sankyo's mirogabalin successful in late-stage neuropathic pain study
Financials ( JPY)
Sales 2018 929 B
EBIT 2018 -
Net income 2018 63 987 M
Finance 2018 359 B
Yield 2018 2,81%
P/E ratio 2018 26,26
P/E ratio 2019 27,21
EV / Sales 2018 1,52x
EV / Sales 2019 1,64x
Capitalization 1 767 B
Chart DAIICHI SANKYO COMPANY, LI
Duration : Period :
DAIICHI SANKYO COMPANY, LI Technical Analysis Chart | 4568 | JP3475350009 | 4-Traders
Technical analysis trends DAIICHI SANKYO COMPANY, LI
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 2 521  JPY
Spread / Average Target 1,2%
EPS Revisions
Managers
NameTitle
Joji Nakayama President, CEO & Representative Director
Kentaro Takamura IR Contact, Manager-Finance & Accounting
Glenn J. Gormley Senior Managing Executive Officer, Head-R&D
Masahiko Ohtsuki Executive Officer & Senior Manager-Research
Kazunori Hirokawa Representative Director, VP & GM-Administration
Sector and Competitors
1st jan.Capitalization (M$)
DAIICHI SANKYO COMPANY, LIMITED4.16%15 746
JOHNSON & JOHNSON18.42%365 346
NOVARTIS13.23%226 956
ROCHE HOLDING LTD.5.20%215 359
PFIZER11.88%214 265
MERCK AND COMPANY7.68%172 751